Orvida Pharma (formerly Kamari Pharma)

Orvida Pharma is a clinical-stage company developing first-in-class, disease-modifying therapies for rare and underserved severe skin diseases. By targeting the TRPV3 pathway, Orvida is advancing a systemic oral treatment across multiple orphan indications, including Olmsted syndrome, keratodermas and Ichthyosis. With no approved disease-modifying therapies currently available for these conditions, we are committed to addressing significant unmet medical needs through a focused, efficient and mechanism-driven development strategy. Our mission is to restore skin structure and function, reduce disease burden, and reclaim quality of life.